Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.61 |
| ▸ | P4HB | P07237 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28547838 | 1.00 | SRC (0.61) | SRCP4HBGAAMAPTPOLB | |
| SCHEMBL26611316 | 1.00 | SRC (0.61) | SRCP4HBGAAMAPTPOLB | |
| SCHEMBL26611805 | 0.95 | SRC (0.60) | SRCP4HBGAAMAPTPOLB | |
| SCHEMBL28546615 | 0.95 | SRC (0.60) | SRCP4HBGAAMAPTPOLB | |
| SCHEMBL30241818 | 0.95 | SRC (0.60) | SRCP4HBGAAMAPTPOLB | |
| SCHEMBL21062751 | 0.87 | SRC (0.64) | SRCZAP70CTSL | |
| SCHEMBL21062749 | 0.87 | SRC (0.64) | SRCZAP70CTSL | |
| SCHEMBL4115544 | 0.87 | P4HB (0.64) | SRCP4HBGAAMAPTPOLB | |
| SCHEMBL25472768 | 0.84 | SRC (0.57) | SRCP4HBGAAMAPTPOLB | |
| SCHEMBL30241796 | 0.84 | SRC (0.57) | SRCP4HBGAAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118725014-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-111954539-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4218785-A2 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-3723783-B1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795196-B2 | Mitochondria-targeting peptides | HSPE1, TFAM, TNNI3 | SRC 4679/4885P4HB 1197/4885GAA 1795/4885 |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | SRC 4679/4885P4HB 1197/4885GAA 1795/4885 |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | SRC 4679/4885P4HB 1197/4885GAA 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.